The U.S. Food and Drug Administration has approved a new oral treatment combination for adults with relapsed or refractory multiple myeloma, offering a chemotherapy-free option for patients who have already tried at least two prior therapies. The decision marks the first approval for the novel drug iberdomide, which will be used alongside dexamethasone in this patient population.
Multiple myeloma is a cancer of plasma cells in the bone marrow, and while many patients respond to initial treatment, the disease often returns. For those who relapse after two or more lines of therapy, options become more limited and side effects more challenging. The new regimen works by targeting a protein called IKZF1/3, which helps degrade specific transcription factors that myeloma cells depend on for survival. This mechanism is distinct from older immunomodulatory drugs, potentially offering a new avenue for patients whose cancer has become resistant to existing treatments.
In the pivotal clinical trial supporting the approval, the iberdomide and dexamethasone combination produced an overall response rate of 32.5% among heavily pretreated patients. The median duration of response was 11.1 months, and the median progression-free survival reached 4.4 months. Notably, responses were seen across high-risk subgroups, including patients with chromosomal abnormalities and those refractory to lenalidomide or pomalidomide. The most common side effects included low white blood cell counts, fatigue, and respiratory infections, which were manageable with dose adjustments and supportive care.
What This Means for Patients and Next Steps
For clinicians, the approval adds a much-needed oral option that can be administered at home, reducing the burden of frequent infusion center visits. Because iberdomide works differently than existing drugs in its class, it may benefit patients who have exhausted other immunomodulatory therapies. The FDA granted the approval under its accelerated pathway, meaning the drug maker will need to confirm clinical benefit in a confirmatory trial currently underway.
Patients should discuss with their oncology team whether this regimen is appropriate based on their prior treatments, blood counts, and overall health. The drug is expected to become available in the coming weeks, and patient assistance programs are being established to support access. Researchers are also studying iberdomide in earlier lines of therapy and in combination with other agents, which could expand its use in the future. For now, the approval provides a new, tolerable option for a group of patients who have long needed more choices after relapse.